Skip to content
MarketScale
‹ Back to Industries

Sciences

Biologists Figured Out How to Generate New Neurons in the Adult Brain, Revolutionizing Neurodegenerative Disease Research

Recently biologists discovered how to generate new neurons in the adult brain. This is an incredible breakthrough that has enormous potential to revolutionize neurodegenerative disease research. By generating genetically-mutated mice with a unique gene that activates dormant neural stem cells, scientists were able to generate new neurons in the brain. For years, scientists have…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Leslie Samuel · Brain FunctionInteractive BiologyLeslie SamuelNeurodegenerative Diseases
Share

Key takeaways

01

Recently biologists discovered how to generate new neurons in the adult brain.

02

This is an incredible breakthrough that has enormous potential to revolutionize neurodegenerative disease research.

03

By generating genetically-mutated mice with a unique gene that activates dormant neural stem cells, scientists were able to generate new neurons in the brain.

Recently biologists discovered how to generate new neurons in the adult brain. This is an incredible breakthrough that has enormous potential to revolutionize neurodegenerative disease research. By generating genetically-mutated mice with a unique gene that activates dormant neural stem cells, scientists were able to generate new neurons in the brain. For years, scientists have been searching for ways to promote the growth of new neurons in the brain, especially in individuals with neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This new discovery could lead to new treatments and therapies that could help to restore brain function and improve the quality of life for millions of people around the world.

Leslie Samuel, founder of Interactive Biology, gives some context for the importance of genetic trading between organisms for scientific research, and notes how the loss of nerve cells in the brain is one of the hallmarks of neurodegenerative diseases. The ability to generate new neurons in the adult brain could be a game-changer in the field of neurology.

Leslie’s Thoughts

“Anytime you have a situation where extracts from one organism can have beneficial effects on another organism, especially if that other organism is a human, I think it’s an exciting thing. In my last video I spoke about how certain cordyceps fungi can have anti-cancer effects. But it doesn’t stop there.

In fact, studies are beginning to show that some compounds that are extracted from certain species of cordyceps can help to protect neurons from damage and even promote their growth by increasing the production of nerve growth factor. This has potentially huge implications for people suffering with neurodegenerative diseases, things like Alzheimer’s disease or Parkinson’s disease, because these diseases are characterized by a loss of nerve cells in the brain.

So if we can somehow stimulate the exact opposite nerve cell growth, that could be very helpful. But it’s important to understand that we’re still relatively early in this process of studying whether this can be beneficial in therapies in the future. But regardless, it’s awesome to see the progress that’s been made so far, and it’s exciting to think about what that could mean for the future.”

Article written by Galina Mikova.

About the author

Leslie Samuel

Leslie Samuel's journey is a testament to determination and passion. Although his dream of becoming a university professor was initially hampered by the lack of a Ph.D., he didn't let that stop him. Instead, he embraced the digital age, becoming a prominent blogger and YouTuber. Through these platforms, Leslie shared his knowledge, effectively teaching what he would have taught in a classroom, reaching hundreds of thousands of eager learners worldwide. His online success opened doors, leading to his dream job as a university professor in a Doctor of Physical Therapy program, despite the absence of a Ph.D. However, Leslie's impact online was undeniable, prompting him to make the bold decision to transition into a full-time blogger and business coach. Today, through Interactive Biology, Leslie Samuel continues to demonstrate that Biology is not only educational but also immensely enjoyable. His journey is a shining example of how determination and innovation can turn dreams into reality.

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Leslie Samuel's journey is a testament to determination and passion. Although his dream of becoming a university professor was initially hampered by the lack of a Ph.D., he didn't let that stop him. Instead, he embraced the digital age, becoming a prominent blogger and YouTuber. Through these platforms, Leslie shared his knowledge, effectively teaching what he would have taught in a classroom, reaching hundreds of thousands of eager learners worldwide. His online success opened doors, leading to his dream job as a university professor in a Doctor of Physical Therapy program, despite the absence of a Ph.D. However, Leslie's impact online was undeniable, prompting him to make the bold decision to transition into a full-time blogger and business coach. Today, through Interactive Biology, Leslie Samuel continues to demonstrate that Biology is not only educational but also immensely enjoyable. His journey is a shining example of how determination and innovation can turn dreams into reality.